PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.81
+0.04 (+1.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.77
Open2.77
Bid2.77 x 38500
Ask2.83 x 3000
Day's Range2.77 - 2.84
52 Week Range2.15 - 3.55
Volume603,240
Avg. Volume1,620,866
Market Cap423.301M
Beta0.06
PE Ratio (TTM)3.96
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-02
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PDL BioPharma Names Dr. Jill Jene Vice President, Business Development
    PR Newswire6 days ago

    PDL BioPharma Names Dr. Jill Jene Vice President, Business Development

    INCLINE VILLAGE, Nev., May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) announces the appointment of Jill M. Jene, Ph.D. as Vice President, Business Development. Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and companies. She will report to PDL President, Dominique Monnet. "Jill brings to PDL more than 20 years of biopharmaceutical business development experience and an exceptional track-record of success spanning more than $3 billion in licensing and M&A transactions," said Mr. Monnet. "We look forward to her expertise in identifying opportunities and creating novel deal structures that support our goal of increasing shareholder value by expanding our portfolio of biopharmaceutical companies and products.

  • PDL BioPharma to Present at Two Upcoming Investor Conferences
    PR Newswire12 days ago

    PDL BioPharma to Present at Two Upcoming Investor Conferences

    INCLINE VILLAGE, Nev. , May 15, 2018 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will present at the following two upcoming investor conferences: UBS Global ...

  • PDL BioPharma Announces First Quarter 2018 Financial Results
    PR Newswire18 days ago

    PDL BioPharma Announces First Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , May 9, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2018 including: Total ...

  • GlobeNewswire19 days ago

    Investor Expectations to Drive Momentum within Masco, Murphy Oil, NGL Energy Partners LP, PBF Energy, PDL BioPharma, and Phillips 66 — Discovering Underlying Factors of Influence

    NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Masco ...

  • PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018
    PR Newswire25 days ago

    PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018

    INCLINE VILLAGE, Nev. , May 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it will release its first quarter 2018 financial results for the period ...

  • PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
    PR Newswirelast month

    PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018

    INCLINE VILLAGE, Nev. , April 16, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June ...

  • PR Newswire2 months ago

    PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant Concerns

    CHICAGO, April 9, 2018 /PRNewswire/ -- SevenSaoi Capital, LLC (together with its affiliates, "SevenSaoi," pronounced "7C"), a long-only public equity investment firm that owns 2,590,198 shares of common stock of PDL BioPharma, Inc. (PDLI) ("PDL" or the "Company"), is pleased that, following SevenSaoi's nomination of Shlomo Yanai to the PDL Board, the Company has added Mr. Yanai to its slate of director nominees for PDL's 2018 Annual Meeting. SevenSaoi introduced and nominated Mr. Yanai to the PDL Board as part of a slate of highly-qualified director candidates in March 2018.

  • PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference
    PR Newswire2 months ago

    PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference

    INCLINE VILLAGE, Nev. , April 3, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that Peter Garcia , PDL's vice president and chief financial officer, will ...

  • PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results
    PR Newswire3 months ago

    PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results

    Total Revenues Increased by 31% in 2017 GAAP EPS Increased 350% and 82% for Q417 and FY 2017, respectively INCLINE VILLAGE, Nev. , March 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) ...

  • ACCESSWIRE3 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern Time. ...

  • GlobeNewswire3 months ago

    Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharma, and Dollar General — Future Expectations, Projections Moving into 2018

    NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018
    PR Newswire3 months ago

    PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018

    INCLINE VILLAGE, Nev., March 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (PDLI) today announced that the Company will release its fourth quarter, year-end 2017 financial results for the period ended December 31, 2017, on Thursday March 8, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.

  • Business Wire3 months ago

    Richard L. Lindstrom, M.D. Joins LENSAR, Inc. Board of Directors

    LENSAR, Inc., an emerging leader in next generation femtosecond laser technology for refractive cataract surgery, today is pleased to announce world renowned ophthalmologist Richard L.

  • PR Newswire3 months ago

    Neos Therapeutics Reiterates Confidence in Strategic Plan and Value Creation Opportunities

    DALLAS and FORT WORTH, Texas , Feb. 20, 2018 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release ...

  • PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos
    PR Newswire3 months ago

    PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos

    -- PDL does not plan to make any further proposals to acquire Neos -- INCLINE VILLAGE, Nev. , Feb. 20, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today officially announced it will no longer ...

  • PDL BioPharma to Present at Two Upcoming Investor Conferences
    PR Newswire3 months ago

    PDL BioPharma to Present at Two Upcoming Investor Conferences

    INCLINE VILLAGE, Nev. , Feb. 14, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's chief executive officer, will present at the following two ...

  • PR Newswire6 months ago

    Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older

    DUBLIN , Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced ...

  • PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
    PR Newswire7 months ago

    PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process

    INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares. PDL is confident its proposal represents fair value for the Company and offers certain and compelling value for Neos shareholders.

  • PDL BioPharma to Present at Two Upcoming Investor Conferences
    PR Newswire7 months ago

    PDL BioPharma to Present at Two Upcoming Investor Conferences

    INCLINE VILLAGE, Nev. , Nov. 7, 2017 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two ...

  • ACCESSWIRE7 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 2, 2017 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern ...

  • PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
    PR Newswire7 months ago

    PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal

    INCLINE VILLAGE, Nev. , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, ...

  • PR Newswire7 months ago

    Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma

    DALLAS and FORT WORTH, Texas, Oct. 30, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Neos noted that PDL's October proposal is identical in all material respects to proposals received in June, July and September from PDL, which were also reviewed and unanimously rejected by the Neos Board. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Neos Board affirmed its previous determinations that PDL's proposal undervalues Neos, does not reflect Neos' strategic value and future prospects for continued growth and value creation, and is not in the best interests of the Company or Neos shareholders.

  • PDL BioPharma Announces Settlement Agreement with Valeant
    PR Newswire7 months ago

    PDL BioPharma Announces Settlement Agreement with Valeant

    INCLINE VILLAGE, Nevada, Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) today announced that on October 27, 2017, PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. and its indirect subsidiary Valeant Pharmaceuticals Luxembourg S.à r.l.

  • PR Newswire7 months ago

    Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharma

    DALLAS and FORT WORTH, Texas, Oct. 26, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the Neos Board of Directors will carefully review and consider the PDL proposal to determine the course of action that it believes is in the best interest of the Company and Neos shareholders.